Cash Flow Statement (Annual)
CAA / CalAtlantic Group, Inc. Cash Flow Statement shows changes in cash positions over time. Cash Flow Statement data includes Cash from Operating Activities (CFOP), Cash from Investing Activities, and Cash from Financing Activities.
All numbers are times 1,000 except per share units.
|Cash Flows From Operating Activities|
|Net Income Loss||-13,786||-11,724||-16,417||531,421||188,715||215,865||213,509||484,730|
|Adjustments To Reconcile Net Income Loss To Net Cash Provided By Used In Operating Activities|
|Adjustments To Reconcile Net Income To Net Cash Provided By Used In Operating Activities|
|Income Loss From Equity Method Investments||-4,598||1,166||207||-2,090||949||-668||1,966||4,057|
|Equity Method Investment Dividends Or Distributions||3,465||-||20||3,910||3,375||1,875||2,830||-|
|Depreciation Depletion And Amortization||3,516||3,002||3,255||2,480||3,576||4,928||41,151||61,704|
|Gain Loss On Sale Of Property Plant Equipment||2,611||37||179||-37||-17||-11||-39||-|
|Share Based Compensation||12,864||11,848||11,239||7,151||9,015||8,469||15,624||17,794|
|Excess Tax Benefit From Share Based Compensation Operating Activities||-297||27||-||-||-||13,404||9,250||460|
|Increase Decrease In Deferred Income Taxes||-||-||-||454,000||-84,214||-98,998||-38,636||5,097|
|Impairment Of Real Estate And Deposit Write Offs||-||1,918||15,334||133||-||-||-||-|
|Net Cash Provided By Used In Operating Activities Continuing Operations||-||-||-||-||-154,216||-362,397||-271,361||-|
|Changes In Cash And Equivalents Due To|
|Increase Decrease In Accounts And Notes Receivable||8,440||-6,541||-5,358||-801||3,244||4,777||-||-|
|Increase Decrease In Mortgage Loans Held For Sale Net||24,718||-12,165||-43,661||46,339||2,543||52,838||42,871||-63,649|
|Increase Decrease In Inventory Real Estate Owned||326,062||148,706||-282,447||315,639||415,312||642,008||497,836||306,896|
|Increase Decrease In Inventory Real Estate Not Owned||-2,805||27,861||-19,727||31,551||43,319||33,027||-34,770||37,728|
|Increase Decrease In Prepaid Deferred Expense And Other Assets||118,265||-111,496||6,212||-2,618||-965||-9,306||2,998||-5,697|
|Increase Decrease In Accounts Payable||-18,554||-6,592||1,113||4,617||13,325||9,314||-89,461||20,099|
|Increase Decrease In Accrued Liabilities||-22,576||-61,843||7,852||9,155||7,949||34,223||26,462||21,541|
|Net Cash Provided By Used In Operating Activities||419,830||-80,958||-322,613||-283,116||-154,216||-362,397||-271,361||322,314|
|Cash Flows From Investing Activities|
|Payments To Acquire Interest In Joint Venture||28,600||39,513||14,689||57,458||24,328||10,506||91,453||29,118|
|Proceeds From Dividends Received||3,524||7,640||8,593||14,530||4,763||18,010||19,582||39,735|
|Cash Acquired From Acquisition||-||-||-||-||-||-||268,517||-|
|Payments To Acquire Businesses Net Of Cash Acquired||-||-||-||60,752||116,262||33,770||-||-|
|Payments For Proceeds From Other Investing Activities||2,225||1,582||2,217||1,525||8,030||4,754||11,972||7,688|
|Net Cash Provided By Used In Investing Activities Continuing Operations||-||-||-||-||-143,857||-31,020||184,674||-|
|Net Cash Provided By Used In Investing Activities||-27,301||-33,455||-8,313||-105,205||-143,857||-31,020||184,674||2,929|
|Cash Flows From Financing Activities|
|Proceeds From Repayments Of Restricted Cash Financing Activities||-9,748||-12,843||-1,559||3,347||6,565||-16,762||652||8,873|
|Proceeds From Repayments Of Secured Debt||-125,984||-83,562||-1,207||-866||-8,334||-1,458||-||-|
|Proceeds From Lines Of Credit||-||-||-||-||-||-||852,700||1,433,200|
|Maturities Of Senior Debt||-||-||-||-||-||4,971||29,789||-|
|Repayments Of Senior Debt||-||792,389||-||49,603||-||4,971||29,789||280,000|
|Repayments Of Lines Of Credit||-||-||-||-||-||-||852,700||1,433,200|
|Proceeds From Issuance Of Senior Long Term Debt||257,592||977,804||-||253,000||300,000||300,000||-||300,000|
|Repayments Of Secured Debt||-||-||-||-||8,334||1,458||2,532||23,228|
|Proceeds From Payments On Mortgage Credit Facilities||22,660||10,651||-16,464||-45,351||-8,708||11,454||-110,469||55,995|
|Payments Of Debt Issuance Costs||8,764||17,215||4,575||11,761||5,316||6,230||1,016||2,669|
|Payments Of Stock Issuance Costs||-||-||324||-||-||-||-||-|
|Proceeds From Stock Options Exercised||641||2,611||1,278||13,039||13,536||6,771||1,000||-|
|Proceeds From Issuance Of Common Stock||-||186,443||-||71,847||-||-||-||-|
|Net Cash Provided By Used In Financing Activities||-422,815||250,225||10,077||324,354||314,809||242,519||60,888||-303,710|
|Payments For Repurchase Of Common Stock||-||-||-||-||-||36,781||22,073||232,520|
|Cash And Cash Equivalents Period Increase Decrease||-30,286||135,812||-320,849||-63,967||16,736||-150,898||-25,799||21,533|
|Payment Of Financing And Stock Issuance Costs||-||-||-||-||-||-||-||-|
|Excess Tax Benefit From Share Based Compensation Financing Activities||297||27||-||-||-||13,404||9,250||-|
|Cash And Cash Equivalents At Carrying Value||-||-||410,522||346,555||363,291||212,393||186,594||208,127|
|Payments Of Dividends Common Stock||-||-||-||-||-||-||4,851||18,841|
|Homebuilding Restricted Cash At End Of Period||-||-||31,372||26,900||21,460||38,222||35,990||28,321|
|Financial Services Restricted Cash At End Of Period||-||-||1,295||2,420||1,295||1,295||22,914||21,710|
|Cash And Equivalents And Restricted Cash At End Of Period||-||-||443,189||375,875||386,046||251,910||245,498||258,158|
|Proceeds From Payments For Other Financing Activities||-||-||-||-||-||-||-222||-200|
|Net Cash Provided By Used In Financing Activities Continuing Operations||-||-||-||-||314,809||242,519||60,888||-|
Peers - Operative Builders (1531)
CCS / Century Communities Inc.
DHI / D.R. Horton, Inc.
HOV / Hovnanian Enterprises, Inc.
KBH / KB Home
MDC / M.D.C. Holdings, Inc.
MHO / M/I Homes, Inc.
MTH / Meritage Homes Corp.
2018-05-25 - Asif
Overview Heron is a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments that address some of the most important unmet patient needs. Heron Therapeutics is developing novel, patient-focused solutions that apply its innovative science and technologies to already approved pharmacological agents for patients suffering from cancer or pain. On August 9, 2016, its first commercial product, SUSTOL, was approved by the FDA. The company developed SUSTOL for the prevention of chemotherapy-induced nausea and vomiting (“CINV”). SUSTOL is indicated, in combination with other antiemetics, in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy (“MEC”) or anthracycline and cyclophosphamide (“AC”) combination chemotherapy regimens. The company commenced commercial sales of SUSTOL in the U.S. in October 2016. On November 9, 2017...
2018-05-25 - Asif
Overview The company's mission is to deliver high-speed coherent optical interconnect products that transform communications networks, relied upon by cloud infrastructure operators and content and communication service providers, through improvements in performance and capacity and reductions in associated costs. By converting optical interconnect technology to a silicon-based technology, a process the company refer to as the siliconization of optical interconnect, the company believe Acacia Communications is leading a disruption that is analogous to the computing industry’s integration of multiple functions into a microprocessor. The company's products include a family of low-power coherent digital signal processor application-specific integrated circuits, or DSP ASICs, and silicon photonic integrated circuits, or silicon PICs, which Acacia Communications has integrated into families of optical interconnect modules with transmission speeds ranging from 100 to 400 gigabits per ...
2018-05-21 - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
as of ET